Database : MEDLINE
Search on : peripheral and blood and stem and cell and transplantation [Words]
References found : 14502 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1451 go to page                         

  1 / 14502 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29517616
[Au] Autor:Robertson MJ; Stamatkin CW; Pelloso D; Weisenbach J; Prasad NK; Safa AR
[Ad] Address:Lymphoma Program and Bone Marrow and Stem Cell Transplantation Program, Department of Medicine, Division of Hematology/Oncology.
[Ti] Title:A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
[So] Source:J Immunother;, 2018 Mar 06.
[Is] ISSN:1537-4513
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Interleukin-18 (IL-18) is an immunostimulatory cytokine that augments antibody-dependent cellular cytotoxicity mediated by human natural killer cells against antibody-coated lymphoma cells in vitro and that has antitumor activity in animal models. Ofatumumab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Cohorts of 3 patients were given intravenous infusions of ofatumumab 1000 mg weekly for 4 weeks with escalating doses of rhIL-18 as a intravenous infusion weekly for 8 consecutive weeks. Nine male patients with CD20 lymphomas were given ofatumumab in combination with rhIL-18 at doses of 3, 10, and 30 µg/kg. No unexpected or dose-limiting toxicities were observed. The mean reduction from predose levels in the number of peripheral blood natural killer cells after the first rhIL-18 infusion was 91%, 96%, and 97% for the 3, 10, and 30 µg/kg cohorts, respectively. Serum concentrations of interferon-γ and chemokines transiently increased following IL-18 dosing. rhIL-18 can be given in biologically active doses by weekly infusions in combination with ofatumumab after peripheral blood stem cell transplantation to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus ofatumumab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:Publisher
[do] DOI:10.1097/CJI.0000000000000220

  2 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29511683
[Au] Autor:Lee SE; Lim JY; Ryu DB; Kim TW; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Min CK
[Ad] Address:Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
[Ti] Title:Circulating CD3 CD4 CD161 Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma.
[So] Source:Biomed Res Int;2018:5097325, 2018.
[Is] ISSN:2314-6141
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The aim of this study was to explore if measurement of pretransplant circulating CD161-expressing cells, in addition to clinical risk factors, could predict mucositis and infections in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT). To determine if CD161-expressing cells are likely to predict early complications, namely, mucositis (≥grade 3), infections, and cytomegalovirus (CMV) reactivation, we prospectively examined CD161-expressing cells (CD3 CD4 CD161 and CD3 CD8 CD161 ) in peripheral blood samples from 108 patients with MM undergoing ASCT. After adjusting for factors identified by univariate analysis that predicted mucositis (≥grade 3), infection before engraftment, and CMV reactivation, multivariate analyses revealed that the low proportion of CD3 CD4 CD161 cells in peripheral blood was an independent predictor of mucositis (≥grade 3) ( = 0.020), infections before engraftment ( = 0.014), and CMV reactivation ( = 0.010). In addition, we found that female sex and decreased glomerular filtration rate were independent factors for predicting mucositis. Female sex and severe pulmonary comorbidity were independent factors for predicting infection before engraftment. We found that the proportion of circulating CD3 CD4 CD161 cells is useful for predicting the occurrence of early complications, including mucositis and infections, after ASCT in patients with MM.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Process
[do] DOI:10.1155/2018/5097325

  3 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523889
[Au] Autor:Chua CC; Lim HY; Chai KL; Ong J; Sim S; Wood C; Dickinson M; Campbell P; Hempton J; King H; Dowsing C; Bergin K; Muir S; Gibbs S; Grigg A
[Ad] Address:Clinical Haematology, Austin Health, Heidelberg, VIC, Australia. cchyn.chua@gmail.com.
[Ti] Title:Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.
[So] Source:Bone Marrow Transplant;, 2018 Mar 09.
[Is] ISSN:1476-5365
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Bortezomib-based induction is often used in transplant-eligible patients with myeloma. The optimal peripheral blood stem cell (PBSC) mobilisation strategy in this context is unclear. We reviewed the efficacy of G-CSF alone (G-alone) vs. G-CSF and cyclophosphamide (G-cyclo: standard dose: 1.5-2 g/m ; high dose: 3-4 g/m ) PBSC mobilisation strategies in 288 patients who only received bortezomib, cyclophosphamide and dexamethasone (VCD) induction prior to autograft across six apheresis centres from November 2012 to June 2017. 'Uncomplicated successful mobilisation' was defined as achieving a PBSC yield of ≥4 × 10 /kg within two aphereses, without plerixafor or mobilisation-associated toxicity (predominantly febrile neutropenia, FN). Success rates were 84% in G-cyclo standard dose (6% FN), 64% in G-cyclo high dose (18% FN) and 69% in G-alone (plerixafor successfully salvaged 8/9 patients). Median total stem cell yield was significantly higher with G-cyclo, but not different between the two cyclophosphamide doses. Age greater than the median of 61 years was associated with higher failure rates (22 vs. 11%, p = 0.01) and lower PBSC yield, especially in the G-alone group. Prior radiotherapy exposure did not impact on collection success. Our observations suggest that both G-cyclo standard dose and G-alone are reasonable mobilisation strategies. The former may be preferred if salvage plerixafor is unavailable.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1038/s41409-018-0152-2

  4 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523881
[Au] Autor:Wang YY; Ma S; Chen Q; Jiao D; Yang Y
[Ad] Address:Department of Biomedical Engineering, College of Life Information Science and Instrument Engineering, Hangzhou Dianzi University, Hangzhou, China. wangyy@hdu.edu.cn.
[Ti] Title:In vivo selection with lentiviral expression of Bcl2 mutant in hematopoietic stem cell-transplanted mice.
[So] Source:Gene Ther;, 2018 Mar 09.
[Is] ISSN:1476-5462
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Current in vivo selections for hematopoietic stem cell (HSC)-based gene therapy are drug dependent and not without risk of cytotoxicity or tumorigenesis. We developed a new in vivo selection system with the non-phosphorylatable Bcl2 mutant Bcl2 (Bcl2 ), which makes in vivo selection drug independent and without risk of cytotoxicity or tumorigenesis. We demonstrated in HSC-transplanted mice that Bcl2 facilitated efficient in vivo selection in the absence of any exogenously applied drugs under both myeloablative and non-myeloablative conditioning. In mice transplanted with retrovirally transduced sca-1-positive bone marrow cells, the marked cell level increased from 26.38% of input transduced cells to 92.61 ± 0.95% of peripheral blood cells for myeloablative transplantation or to 37.82 ± 6.35% for non-myeloablative transplantation 6 months after transplantation. Bcl2 did not induce tumorigenesis and does not influence hematopoiesis and the function of the reconstituted blood system. However, the high-level constitutive expression of Bcl2 mediated by retroviral vector induced exhaustion of the marked cells after tertiary transplantation. Fortunately, low-level constitutive expression of Bcl2 driven by an internal promoter in lentiviral vector could both maintain the marked cell level (24.13 ± 5.27%, 27.17 ± 5.51%, 24.33 ± 5.08%, and 22.07 ± 4.44% for primary, secondary, tertiary, and quaternary recipients) and avoid the exhaustion of the marked cells even in quaternary recipients. Importantly, the low-level constitutive expression of Bcl2 did not induce tumorigenesis. Thus, the in vivo selection employing the low-level constitutive expression of Bcl2 provides a general platform which is relevant for widespread applications of gene therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1038/s41434-018-0008-9

  5 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29377903
[Au] Autor:Koldehoff M; Lindemann M; Ross SR; Elmaagacli AH
[Ad] Address:Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany.
[Ti] Title:Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line.
[So] Source:PLoS One;13(1):e0191482, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cytomegalovirus (HCMV) reactivation is found frequently after allogeneic hematopoietic stem cell transplantation (alloSCT) and is associated with an increased treatment-related mortality. Recent reports suggest a link between HCMV and a reduced risk of cancer progression in patients with acute leukemia or lymphoma after alloSCT. Here we show that HCMV can inhibit the proliferation of the acute myeloid leukemia cell line Kasumi-1 and the promyeloid leukemia cell line NB4. HCMV induced a significant up-regulation of HLA-class-II-molecules, especially HLA-DR expression and an increase of apoptosis, granzyme B, perforin and IFN-γ secretion in Kasumi-1 cells cocultured with peripheral blood mononuclear cells (PBMCs). Indolamin-2,3-dioxygenase on the other hand led only to a significant dose-dependent effect on IFN-γ secretion without effects on proliferation. The addition of CpG-rich oligonucleotides and ganciclovir reversed those antiproliferative effects. We conclude that HCMV can enhance alloreactivity of PBMCs against Kasumi-1 and NB4 cells in vitro. To determine if this phenomenon may be clinically relevant further investigations will be required.
[Mh] MeSH terms primary: Histocompatibility Antigens Class II/immunology
Leukemia, Myeloid, Acute/immunology
[Mh] MeSH terms secundary: Cell Line, Tumor
Coculture Techniques
Humans
Leukemia, Myeloid, Acute/therapy
Leukemia, Myeloid, Acute/virology
Stem Cell Transplantation
Transplantation, Homologous
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Histocompatibility Antigens Class II)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191482

  6 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518828
[Au] Autor:Yu G; Wang WJ; Liu DR; Tao ZF; Hui XY; Hou J; Sun JQ; Wang XC
[Ad] Address:Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai 201102, China.
[Ti] Title:[Clinical characteristics of human recombination activating gene 1 mutations in 8 immunodeficiency patients with diverse phenotypes].
[So] Source:Zhonghua Er Ke Za Zhi;56(3):186-191, 2018 Mar 02.
[Is] ISSN:0578-1310
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:To investigate the clinical characteristics of 8 immunodeficiency cases caused by human recombination activating gene 1 (RAG1) mutations, and to explore the relationship among genotypes, clinical manifestations and immunophenotypes. Clinical data were collected and analyzed from patients with RAG1 mutations who visited the Department of Clinical Immunology, Children's Hospital of Fudan University between October 2013 and June 2017. The data included clinical manifestations, immunophenotypes and genotypes. A total of 8 patients were diagnosed with RAG1 deficiency (6 boys and 2 girls). The minimum age of onset was 2 months, and the maximum age was 4 months. The minimum age of diagnosis was 2 months, and the maximum age was 13 years. Four patients had a family history of infant death due to severe infections. Two cases were born to the same consanguineous parents. All cases had recurrent infections, including involvement of respiratory tract (8 cases), digestive tract (6 cases), urinary tract (1 case), and central nervous system (1 case). The pathogens of infection included bacteria, viruses and fungi. Rotavirus was found in 3 cases, cytomegalovirus (CMV) in 5 cases, bacillus Calmette-Guérin adverse reaction in 2 cases (1 of whom had a positive acid-fast smear from lymph node puncture fluid), fungal infection in 3 cases. One case had multiple nodular space-occupying lesions in lungs and abdominal cavity complicated with multiple bone destruction. The peripheral blood lymphocyte counts of all patients ranged between 0.1 ×10(9)/L and 3.3×10(9)/L (median, 0.65×10(9)/L). Eosinophilia was found in 3 cases (range, (0.48-1.69) ×10(9)/L). The patients were classified according to immunophenotype as severe combined immunodeficiency phenotype (4 cases), leaky severe combined immunodeficiency (2 cases), Omenn syndrome (1 case) and combined immunodeficiency (1 case) . Decreased serum IgG levels were found in 3 cases, increased serum IgM levels in 3 cases, increased serum IgE levels in 5 cases. RAG1 homozygous mutations were detected in 5 cases and RAG1 compound heterozygous mutations in 3 cases. Two novel mutations and six previously reported mutations were identified. Three cases were successfully treated with hematopoietic stem cell transplantation. Four cases died due to infections, and the 13 year-old patient was still under follow-up in the outpatient clinic. Different RAG1 gene mutations can lead to diverse clinical presentations and immune phenotypes. Clinicians should pay attention to the family history of infant death with severe infection. In that situation, immunological evaluation and gene detection should be performed as early as possible.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.3760/cma.j.issn.0578-1310.2018.03.007

  7 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516991
[Au] Autor:Wang H; Ge W; Zhuang Y; Fu J; Li D; Ju X
[Ad] Address:Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong Province, China.
[Ti] Title:Fast recovery of platelet production in NOD/SCID mice after transplantation with expansion of megakaryocyte from cord blood CD34+ cells.
[So] Source:J Cancer Res Ther;14(1):233-239, 2018 Jan.
[Is] ISSN:1998-4138
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Background: Cord blood transplantation (CBT) can be a life-saving procedure in the treatment of a broad variety of disorders, including hematologic, immune, and genetic diseases. However, delayed platelet recovery hinders the application of CBT. Purpose: The aim of this study was to determine the optimal combination of cytokines to amplify megakaryocyte (Mk). Methods: CB CD34+ cells were obtained by immunomagnetic isolation and amplified under four different cytokine combinations. CD34+ cells of the group with thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand (FL), and interleukin-6 (IL-6) were collected on days 0, 3, 7, 10, and 14. Immunophenotype was analyzed by flow cytometry (FCM). Polyploidic Mk cultured cells were collected on days 7 and 14 for colony-forming unit-Mk assay. The NOD/SCID mice were injected with expanded CD34+ cells, and the peripheral blood (PB) and bone marrow (BM) were tested on 3, 7, and 14 days. Results: The group with TPO, SCF, FL, and IL-6 reached the maximal total expansion fold and Mk population at day 7, which was slightly reduced later. After transplantation into NOD/SCID mice with expanded CD34+ cells, the human CD41+ cells were detected in mice PB on day 3 and in BM on day 7, then disappeared after 14 days. The expressing of activated platelet CD 42b+/CD62P+ increased gradually after transplantation. Conclusion: Platelets can recover rapidly in vivo by means of expanded CD34+ cells with various cytokines. In our system, a group of TPO, SCF, FL, and IL-6 represents the best cytokine combination for expansion of Mk progenitor cells from CB CD34+ cells.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.4103/0973-1482.193893

  8 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515253
[Au] Autor:Lamb LS; Pillai S; Langford S; Bowersock J; Stasi AD; Saad A
[Ad] Address:Department of Medicine, Blood and Marrow Transplantation and Cell Therapy Program, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. lslamb@uabmc.edu.
[Ti] Title:Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis.
[So] Source:Bone Marrow Transplant;, 2018 Mar 07.
[Is] ISSN:1476-5365
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1038/s41409-018-0130-8

  9 / 14502 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515238
[Au] Autor:Barbui T; Tefferi A; Vannucchi AM; Passamonti F; Silver RT; Hoffman R; Verstovsek S; Mesa R; Kiladjian JJ; Hehlmann R; Reiter A; Cervantes F; Harrison C; Mc Mullin MF; Hasselbalch HC; Koschmieder S; Marchetti M; Bacigalupo A; Finazzi G; Kroeger N; Griesshammer M; Birgegard G; Barosi G
[Ad] Address:Division of Hematology, Ospedale Giovanni XXIII, Bergamo, Italy.
[Ti] Title:Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
[So] Source:Leukemia;, 2018 Feb 27.
[Is] ISSN:1476-5551
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by the European LeukemiaNet (ELN) consortium. Recommendations were produced by multiple-step formalized procedures of group discussion. A critical appraisal of evidence by using Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methodology was performed in the areas where at least one randomized clinical trial was published. Seven randomized controlled trials provided the evidence base; earlier phase trials also informed recommendation development. Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow examination for diagnosis of polycythemia vera (PV), according to the revised WHO criteria; the search for complementary clonal markers, such as ASXL1, EZH2, IDH1/IDH2, and SRSF2 for the diagnosis of myelofibrosis (MF) in patients who test negative for JAK2V617, CALR or MPL driver mutations. Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea. Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease; in case of intermediate-1 disease, ruxolitinib is recommended in highly symptomatic splenomegaly. Allogeneic stem cell transplantation is recommended for transplant-eligible MF patients with high or intermediate-2 risk score. Allogeneic stem cell transplantation is also recommended for transplant-eligible MF patients with intermediate-1 risk score who present with either refractory, transfusion-dependent anemia, blasts in peripheral blood > 2%, adverse cytogenetics, or high-risk mutations. In these situations, the transplant procedure should be performed in a controlled setting.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1038/s41375-018-0077-1

  10 / 14502 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29515065
[Au] Autor:Iino M; Yamamoto T
[Ad] Address:Department of Hematology, Yamanashi Prefectural Central Hospital.
[Ti] Title:[Efficacy and safety of biosimilar filgrastim for autologous peripheral blood stem cell harvest and transplantation: a single-institutional retrospective analysis].
[So] Source:Rinsho Ketsueki;59(2):145-152, 2018.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:Three biosimilar filgrastim products are currently available in Japan. Among these, the safety and efficacy of two imported drugs for autologous peripheral blood stem cell harvest (autoPBSCH) and autologous peripheral blood stem cell transplantation (autoPBSCT) have been studied widely; however, evidence of the safety and efficacy of domestically manufactured filgrastim is limited. Therefore, we compared the efficacy and safety of domestic biosimilar filgrastim (BF1, n=23) with those of originator filgrastim (OF, n=21) for autoPBSCH and autoPBSCT. Before autoPBSCH, the same median total dose of 3.3 mg filgrastim was administered to patients in the BF1 and OF groups. Median numbers of CD34-positive cells harvested did not significantly differ between BF1 (4.32×10 /kg) and OF (4.75×10 /kg) groups. After autoPBSCT, the median total doses of BF1 and OF used for neutrophil recovery were 2.7 and 3.3 mg, respectively. There were no significant inter-group differences in the time to bone marrow recovery, total transfusion units, hospitalization duration, overall survival at 1 year, or adverse events. Compared with OF, the cost of BF1 was considerably lower by 229,529 yen per transplantation case. Thus, the efficacy and safety of BF1 were comparable to those of OF, making BF1 an effective and economical alternative to OF.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.11406/rinketsu.59.145


page 1 of 1451 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information